

APOTEX

ABOUT US ▾

PORTFOLIO ▾

NEWS ▾

CAREERS ▾

PARTNERSHIPS ▾

Search



A FORCE FOR HEALTH

LEARN MORE

6000+ ~70

team members
worldwide

~70

countries
served

25B


dose manufacturing
capacity

~800

pharmaceutical &
consumer health
products

50

years and
counting





Latest news

[VIEW ALL NEWS >](#)

Jul 17, 2026

Apotex Receives Investment Grade Issuer Rating from Morningstar...



Toronto, ON, July 16, 2026. Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX) today announced the successful completion of an amended and restated credit agreement ("Amended Credit Agreement"), establishing a financing framework aligned with the Company's evolution as a publicly traded, investment-grade-rated issuer.

Jul 8, 2026

Apotex expands U.S. hospital portfolio with launch of generic...



Toronto, ON, July 8, 2026 – Apotex Health Corp. ("Apotex") (TSX: APTX) today announced the U.S. launch of four product configurations of its generic equivalents of Infuvite® Pediatric Injection and Infuvite® Adult Injection. Of the four configurations launched, the Adult Bulk and Pediatric Single presentations received Competitive Generic Therapy (CGT) exclusivity.

Jul 1, 2026

Apotex completes previously announced strategic transaction with...



TORONTO, July 1, 2026 /CNW/ – Apotex Health Corp. ("Apotex") (TSX: APTX), the largest Canadian-based pharmaceutical company, today announced the closing of its previously announced strategic transaction with Cumberland Pharmaceuticals Inc. ("Cumberland"), a U.S. biopharmaceutical company, to integrate Cumberland's U.S. branded businesses into Apotex.

APOTEX
Canadian-Based
Global Health Company

About us

- Our purpose
- Our leadership
- Global reach
- Manufacturing excellence
- Our impact
- Ethics and compliance

Statement of Resilience

Portfolio

- Generics
- Biosimilars
- Innovative & specialty medicines
- Consumer health

News

Partnerships

Business development inquiries

Investors

Contact us

Legal

Investor Relations Contact



Latest news

[VIEW ALL NEWS](#) ➤

Jul 17, 2026

Apotex Receives Investment Grade Issuer Rating from Morningstar...



Toronto, ON, July 16, 2026. Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX) today announced the successful completion of an amended and restated credit agreement ("Amended Credit Agreement"), establishing a financing framework aligned with the Company's evolution as a publicly traded, investment-grade-rated issuer.

Jul 8, 2026

Apotex expands U.S. hospital portfolio with launch of generic...



Toronto, ON, July 8, 2026 – Apotex Health Corp. ("Apotex") (TSX: APTX) today announced the U.S. launch of four product configurations of its generic equivalents of Infuvite® Pediatric Injection and Infuvite® Adult Injection. Of the four configurations launched, the Adult Bulk and Pediatric Single presentations received Competitive Generic Therapy (CGT) exclusivity.

Jul 1, 2026

Apotex completes previously announced strategic transaction with...



TORONTO, July 1, 2026 /CNW/ – Apotex Health Corp. ("Apotex") (TSX: APTX), the largest Canadian-based pharmaceutical company, today announced the closing of its previously announced strategic transaction with Cumberland Pharmaceuticals Inc. ("Cumberland"), a U.S. biopharmaceutical company, to integrate Cumberland's U.S. branded businesses into Apotex.

APOTEX
Canadian-Based
Global Health Company

About us

- Our purpose
- Our leadership
- Global reach
- Manufacturing excellence
- Our impact
- Ethics and compliance
- Stories of Resilience

Portfolio

- Generics
- Biosimilars
- Innovative & specialty medicines
- Consumer health

News

- Media inquiries

Careers

- Working with us
- Our winning culture

Partnerships

- Business development inquiries

Investors

Contact us

Legal

- Legal & copyright terms
- Privacy policy
- Manage cookies

Document title: APOTEX - A Force For Health.

Capture URL: <https://www.apotex.com/global>

Page loaded at (UTC): Wed, 22 Jul 2026 08:22:46 GMT

Capture timestamp (UTC): Wed, 22 Jul 2026 08:22:48 GMT

Capture tool: 11.2.1

Collection server IP: 54.145.42.72

Browser engine: Mozilla/5.0 (X11; Linux x86_64) AppleWebKit/537.36 (KHTML, like Gecko) @page-vault/browser/11.2.1 Chrome/148.0.7778.280 Safari/537.36

Operating system: Linux (Node 24.18.0)

PDF length: 4

Capture ID: ruVza2PhehzRmwzUmanwj9

Display Name: Alan.Man